Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Barinthus Biotherapeutics (BRNS) Shares Outstanding (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Shares Outstanding readings, the most recent being $40.8 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 1.26% to $40.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $40.8 million, a 1.26% increase, with the full-year FY2025 number at $40.8 million, up 64286.76% from a year prior.
  • Shares Outstanding hit $40.8 million in Q1 2026 for Barinthus Biotherapeutics, roughly flat from $40.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $40.8 million in Q4 2025 to a low of $63443.0 in Q3 2022.
  • Median Shares Outstanding over the past 5 years was $37.2 million (2022), compared with a mean of $21.2 million.
  • The widest YoY moves for Shares Outstanding: up 64286.76% in 2025, down 99.84% in 2025.
  • Barinthus Biotherapeutics' Shares Outstanding stood at $37.7 million in 2022, then plummeted by 99.83% to $63443.0 in 2023, then changed by 0.0% to $63443.0 in 2024, then surged by 64286.76% to $40.8 million in 2025, then changed by 0.0% to $40.8 million in 2026.
  • The last three reported values for Shares Outstanding were $40.8 million (Q1 2026), $40.8 million (Q4 2025), and $40.8 million (Q3 2025) per Business Quant data.